Read further: Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease
Most Recent Articles
Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease
The optimal coronary revascularization strategy in left main coronary artery disease (LMCAD) and three-vessel disease (3VD) is highly debatable among medical professionals. Coronary artery bypass grafting (CABG) is demonstrated...
Management of Patients With a Patent Foramen Ovale With History of Stroke or TIA
A patent foramen ovale (PFO), or what we call the hole that forms between the left and right atria of the heart, is relatively common and is known to occur in about one (1) out of four (4) people. The closure of this PFO brings...
Alirocumab’s Effects on Coronary Plaque: The PACMAN-AMI Clinical Trial
Schwartz et al (2018) reported that previous results under the ODYSSEY OUTCOMES trial showed the risk-reducing effect of alirocumab, a proprotein convertase subtilisin-kexin type 9 inhibitor (PCSK9i), when added to high-intensity...
Effects of Randomized Treatment With Icosapent Ethyl and a Mineral Oil Comparator on Interleukin-1β, Interleukin-6, C-Reactive Protein, Oxidized Low-Density Lipoprotein Cholesterol, Homocysteine, Lipoprotein(a), and Lipoprotein-Associated Phospholipase A2: A REDUCE-IT Biomarker Substudy
The Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial (REDUCE-IT) earlier reported a 25% decrease in relative risk for major adverse cardiovascular events when using ethyl eicosapentaenoic acid (icosapent...